Abeona Therapeutics ABEO 深 滬
已收盤 02-06 16:00:00 美东时间
5.13
+0.230
+4.69%
華盛通- 最 高5.16
- 今 開4.99
- 成交量 87.87万股
- 最 低 4.9301
- 昨 收 4.90
- 總市值 2.78亿
- 52周最高 7.5401
- 市盈率 靜 --
- 換手率 1.62%
- 52周最低 3.9328
- 委 比 -13.27%
- 總股本 5419.14万
- 歷史最高 750.00
- 量 比 0.92
- 振 幅 4.69%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Ultragenyx Pharmaceutical Inc. has resubmitted its BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A, to the FDA, including long-term data and responses to previous CRL observations. The submission aims to secure accelerated approval, supported by robust neurodevelopmental and biomarker data. The FDA previously granted Priority Review, with a PDUFA date expected in Q3 2026. If approved, UX111 would be the first treatment for MPS ...
01-30 13:30
Abeona Therapeutics Director Mark Alvino Reports Disposal of Common Shares
Abeona Therapeutics Director Mark Alvino Reports Disposal of Common Shares Mark Alvino, Director, reported a disposal of common shares of Abeona Therapeutics Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using gener
01-22 05:31
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock equity awards to seven new employees, totaling up to 79,584 shares, which vest annually over three years. The company, focused on cell and gene therapies for serious diseases, recently launched ZEVASKYN®, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa.
2025-12-31 12:30
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
<p>Abeona Therapeutics Inc. announced the appointment of Mohamad Tabrizi as Senior Vice President and Chief Business Officer. Tabrizi will lead corporate strategy, business development, and operational efficiency. He brings extensive experience in strategic planning, venture capital, and corporate development, including successful transactions with major pharmaceutical companies. Previously, he held roles as a General Partner at Pandect Bioventur...
2025-12-15 12:30
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
Abeona Therapeutics announced the first commercial use of ZEVASKYN, the first autologous gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The treatment was administered at Lucile Packard Children’s Hospital Stanford. CEO Vish Seshadri expressed pride in this milestone and gratitude to the medical network. ZEVASKYN uses the COL7A1 gene to help produce functional type VII collagen, addressing a cr...
2025-12-08 12:30
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to two new non-executive employees, totaling up to 45,685 restricted shares. The shares vest equally over three years, contingent on continued employment. Abeona Therapeutics is a biopharmaceutical company focused on cell and gene therapies for serious diseases, with its lead product ZEVASKYN® for recessive dystrophic epidermolysis bullosa.
2025-12-01 12:30
美股牛股 | BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；昂跑涨18%
BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；ONON涨18%，Q3净销售额7.94亿瑞士法郎高于预期，上调年度收入展望>>
2025-11-13 14:54
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
Abeona Therapeutics shares are trading higher after the company reported better...
2025-11-13 00:52
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of $(0.63) per share
2025-11-12 20:31
